Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Bernd Kalthof

Stefan Golz

Svetlana Markova

Ludmila Frank

Eugene Vysotski

Pierre Wasnaire

Klemens Lustig

Martina Delbeck

Frank Süβmeier

Michael Härter

Nils Burkhardt

Andreas Schade

Klaus Ochmann

Michael Harnau

Karl-Hermann Koeching

Mike Küster

Georg Schmidt

Linn Schneider

Dirk Kosemund

Niels Lindner

Raimund Kast

Frank Süssmeier

A dispensing device includes a housing having at least one pressure chamber, having a supply opening for the supply of liquid into the pressure chamber and having a multiplicity of conduits between the pressure chamber and an external side of the housing, there being situated in each of the conduits a tube, the first end of which protrudes into the pressure chamber and the second end of which protrudes out of the housing on the external side.

Metering device

A method and a system for rapid kinetic fluorescence measurement in high-throughput screening with high time-resolution includes providing a microtiter plate having a transparent base and multiple assay wells, a dispensing system arranged above the microtiter plate for simultaneously adding liquid into multiple assay wells, an illumination system beneath the microtiter plate for illuminating the multiple assay wells simultaneously through the transparent base, a detection system for detecting electromagnetic radiation from the multiple assay wells simultaneously through the transparent base, adding 0.3-300 &#x3bc;l of liquid per assay well from the dispensing system into the multiple assay wells, illuminating the multiple assay wells simultaneously through the transparent base using the illumination system before or from the time point of the start of the addition, detecting the electromagnetic radiation from the multiple assay wells simultaneously at a time interval of 1-1000 ms between individual measurement points.

Method and system for taking measurements in a high-throughput screening with high time resolution

The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione ('thienouracil') derivatives bearing a particular type of (azaheterocyclyl)methyl substituent, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.

Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor

The invention relates to the nucleotide and amino acid sequences, and to the activity and use, of the luciferases LuAL, Lu164, Lu16, Lu39, Lu45, Lu52 and Lu22.

Isolated luciferases and the use thereof

The present application relates to novel 2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxamide derivatives ('thienouracil'-carboxamides), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for the preparation of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of pulmonary and cardiovascular disorders.

Cyclic thienouracil-carboxamides and use thereof

This invention relates to an isolated nucleic acid molecule which is a) a nucleic acid molecule comprising SEQ ID No. 3, or b) a nucleic acid molecule which exhibits at least 90% sequence identity to the nucleic acid molecule of SEQ ID No. 3, and the claimed nucleic acid molecule encodes luciferase. It also relates to an expression vector and to a transformed host cell.

Growing community of inventors

Wuppertal, Germany

Bernd Kalthof